Volume 1.22 | Jun 15

Hematopoiesis News 1.22, June 15, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Gamma Interferon Prompts Stem Cell Response to Fight Infection
Invading bacteria can be a call-to-arms, awaking the sleeping stem cells and prompting them to produce immune system cells that fight the foreign organisms. The “bugler” that awakes the stem cells in this battle is gamma interferon. [Press release from Baylor College of Medicine discussing online prepublication in Nature]

Need to expand CD34+ cells?
StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells
WATCH THE VIDEO STEMCELL Technologies Inc


SCIENCE NEWS

Karmanos Cancer Institute Researchers, Collaborators Study Possible Link Between Childhood Leukemia, Gilbert’s Syndrome
Scientists presented preliminary data that identified a potential link between Gilbert’s Syndrome and the development of a specific subtype of childhood acute lymphoblastic leukemia. [Press release from Barbara Ann Karmanos Cancer Institute discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Silk Microchip for Rapid Medical Testing
Researchers have created microchips using silk fibres. In the lab they’ve demonstrated that these microchips can measure oxygen using hemoglobin embedded in the silk. [University of Sydney Press Release]

MethoCult®  
MethoCult®
The most published medium for hematopoietic CFC assays

by STEMCELL Technologies
 
 
TEST YOUR COLONY IDENTIFICATION SKILLS STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Quiescent Hematopoietic Stem Cells are Activated by IFN-Gamma in Response to Chronic Infection
Here researchers show, using an in vivo mouse model of Mycobacterium avium infection, that an increased proportion of long-term repopulating hematopoietic stem cells proliferate during M. avium infection, and that this response requires interferon (IFN)-gamma but not interferon-alpha signalling. [Nature]

Pro Isomerization in MLL1 PHD3-Bromo Cassette Connects H3K4me Readout to CyP33 and HDAC-Mediated Repression
The MLL1 gene is a frequent target for recurrent chromosomal translocations, resulting in transformation of hematopoietic precursors into leukemia stem cells. Here, researchers report on structure-function studies that elucidate molecular events in MLL1 binding of histone H3K4me3/2 marks and recruitment of the cyclophilin CyP33. [Cell]

PD-L1 has Distinct Functions in Hematopoietic and Nonhematopoietic Cells in Regulating T Cell Responses During Chronic Infection in Mice
Here researchers used bone marrow chimeric mice to examine the effects of PD-L1 deficiency in hematopoietic or nonhematopoietic cells during lymphocytic choriomeningitis virus clone 13 (LCMV CL-13) infection. [J Clin Invest]

The Endocytic Adaptor Numb Regulates Thymus Size by Modulating Pre-TCR Signaling During Asymmetric Division
Researchers found that Numb determines the levels of pre-TCR signaling in dividing thymocytes and, ultimately, the size of the pool from which mature T lymphocytes are selected. [Blood]

A Monoclonal Antibody Against Mutated Nucleophosmin1 for the Molecular Diagnosis of Acute Myeloid Leukemias
Mutations in the nucleophosmin 1 (NPM1) gene are the most frequent genetic aberrations of acute myeloid leukemia (AML), and define a clinically distinct subset of AML. A monoclonal antibody (T26) was raised against a 19-aminoacid polypeptide containing the unique C-terminus of the type A NPM1 mutant protein. [Blood]

Telomere Dysfunction and Fusion During the Progression of Chronic Lymphocytic Leukemia: Evidence for a Telomere Crisis
Researchers performed single-molecule telomere length and telomere fusion analysis in patients at different stages of chronic lymphocytic leukemia. [Blood]

BAALC-Associated Gene Expression Profiles Define IGFBP7 as a Novel Molecular Marker in Acute Leukemia
To identify BAALC-associated genes that give insights into its functional role in chemotherapy resistance, gene expression signatures differentiating high from low BAALC expressers were generated from normal CD34+ progenitors, T-acute lymphoblastic leukemia and acute myeloid leukemia samples. [Leukemia]

Effective Targeting of STAT5-Mediated Survival in Myeloproliferative Neoplasms Using ABT-737 Combined with Rapamycin
Here, researchers have retrovirally transduced wild-type or Gab2(-/-) mouse bone marrow cells expressing STAT5(aS711F) and transplanted into irradiated recipient mice to test an in vivo myeloproliferative disease model. [Leukemia]

CLINICAL RESEARCH

Acquired Mutations in the Genes Encoding IDH1 and IDH2 Both are Recurrent Aberrations in Acute Myeloid Leukemia: Prevalence and Prognostic Value
Here, researchers demonstrate in 893 newly diagnosed cases of acute myeloid leukemia mutations in the IDH1 (6%) and IDH2 (11%) genes. [Blood]

Preemptive Alloimmune Intervention in High-Risk Pediatric Acute Lymphoblastic Leukemia Patients Guided by Minimal Residual Disease Level Before Stem Cell Transplantation
Researchers conclude that in children with high-risk acute lymphoblastic leukemia, immunotherapy-based regimens after stem cell transplantation are feasible and may need to be further intensified to achieve total eradication of residual leukemic cells. [Leukemia]


INDUSTRY NEWS

ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. announced updated clinical data from an ongoing Phase I study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc. Press Release]

Hana Biosciences Announces Financing of Up to $100 Million
Hana Biosciences Inc., announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management for the sale of up to $100 million in preferred stock. [Hana Biosciences Inc. Press Release]

Human Genome Sciences Announces Results of Randomized Phase II Trial of Mapatumumab in Multiple Myeloma
Human Genome Sciences, Inc. announced the results of its randomized Phase II trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. [Human Genome Sciences, Inc. Press Release]

Updated Results from Phase II Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Micromet, Inc. announced the presentation of updated results from a Phase II trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease positive acute lymphoblastic leukemia. [Micromet, Inc. Press Release]

BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine
BioSante Pharmaceuticals, Inc. announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA’s Office of Orphan Products Development. [BioSante Pharmaceuticals, Inc. Press Release]


POLICY NEWS

FDA Takes Issue with Genetic Tests from 23andMe, Four Other Firms
The Food and Drug Administration has put five genetic test makers on notice that they must get federal approval before marketing their products for use by consumers. [Food and Drug Administration, United States]

NIH Chief Collins Faces Stem Cell Donation Dilemma
The NIH Advisory Committee to the Director, which advises NIH chief Francis Collins on whether lines meet the Obama ethics guidelines, faced the decision on whether 53 more stem cell lines should be added to that total. [National Institutes of Health, United States]

NIH Researchers Explore How Healthy, Young Adults View the Role Genetics Plays in Improving Health
Most healthy young adults place greater emphasis on health habits than on genetic risk factors when considering what causes common diseases, a research team from the National Human Genome Research Institute and the Henry Ford Health System in Detroit has found. [National Institutes of Health, United States]

NICE Appraisal of Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
Eltrombopag (Revolade, GlaxoSmithKline) is not recommended for treating chronic immune (idiopathic) thrombocytopenic purpura in splenectomised adults who do not respond to other treatments, or as second-line treatment for non-splenectomised adults when surgery is not advised. [National Institute for Health and Clinical Excellence]

Enhancing Peer Review: Advance Notice on Post-Submission Application Materials for NIH Training and Related Applications (NOT-OD-10-104) [National Institutes of Health, United States]

PFINDR: Phenotype Finder IN Data Resources: A Tool to Support Cross-Study Data Discovery Among NHLBI Genomic Studies (UH2/UH3) (RFA-HL-11-020) [National Institutes of Health, United States]

Clinical Trials for Medicines Section Updated [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Advertising and Supply of Therapeutic Goods to Complementary Healthcare Professionals: Schedule 1 to the Therapeutic Goods Regulations [Therapeutic Goods Administration, Australia]

Increased Transparency of the Prescription Medicine Regulatory Process [Therapeutic Goods Administration, Australia]


EVENTS

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)


Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.



Have we missed an important article or publication in Hematopoiesis News? Click here to submit!




Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us